Seasonal Allergy Market Projected for Significant Growth a valuation of USD 2.58 Billion at a 7.8% of CAGR

The global seasonal allergy market was valued at US$ 1.15 billion in 2022 and is anticipated to expand at a CAGR of 7.8% during the forecast period. This upward trend highlights the increasing prevalence of seasonal allergies and the rising demand for effective treatment options.

According to a recent study by Future Market Insights (FMI), the market is largely driven by the growing awareness of allergy management and the availability of innovative treatment forms. Notably, tablets and capsules lead the market with a significant share of approximately 37.1% in 2022, reflecting consumer preference for convenient and effective oral delivery systems.

The rising incidence of allergic reactions due to environmental factors, combined with the increasing use of over-the-counter medications, is expected to bolster market growth. Furthermore, advancements in pharmaceutical research are paving the way for the development of new and more effective therapies for seasonal allergies.

Key players in the seasonal allergy market are focusing on product innovation and strategic partnerships to enhance their market presence and meet the evolving needs of consumers. As awareness and understanding of seasonal allergies continue to grow, the market is poised for robust development in the coming years.

Seasonal allergies, like other allergies, develop when the body’s immune system overreacts to a trigger in the environment, usually in the spring, summer, or fall when specific plants pollinate. A growing number of producers have identified allergies as a viable market, and with the help of a research and development team, they are delivering fresh, cutting-edge therapy and treatment options to the market, expanding the range of already available treatments. A large portion of people are still affected by seasonal allergies yearly.

What are the Key Opportunities for the Manufacturers Operating in the Global Market?

• According to Asthma and Allergy Foundation of America statistics, around 81 million Americans were given seasonal allergic rhinitis (hay fever) diagnosis in 2021. This is roughly 26% of adults (67 million) and 19% (14 million) of children.

This creates an enormous opportunity for the manufacturer to explore the seasonal allergy market. Several biopharma businesses with tested technology and cutting-edge treatment choices that are unique and have been approved have emerged as a result of the life science industry’s entry into the pharmaceutical sector. This enables medical professionals to rely on these novel treatment possibilities.

For instance, allergy immunotherapy as a treatment has proven to be successful in multiple clinical trials. Such as high-dose, standardized vaccinations are used in subcutaneous injection immunotherapy (SCIT). These medications typically contain 5–20 mcg of the main allergen. SCITs are given as maintenance injections every month. Also, sublingual allergy immunotherapy (SLIT) involves the sublingual space’s unique, tolerance-promoting immune cells, also known as oral Langerhans cells. Liquid antigens (drops) and pills are the two therapeutic options for SLIT.

Overall, it is anticipated that the market for seasonal allergies will rise over the coming years as more research and development are put into creating fresh, efficient treatment choices.

Competitive Landscape

Collaboration with scientific and research foundations to increase public awareness and receiving product approvals from regulatory bodies are the key strategies opted by key players within this market space.

• On November 10, 2022, the movement to improve K–12 settings and produce healthier and more beneficial outcomes is being led by Johnson Controls, the world leader in smart, healthy, and sustainable buildings. Johnson Controls is raising awareness about the effects of indoor air quality (IAQ) on children’s academic performance as well as the health of instructors and students in schools in partnership with the Asthma and Allergy Foundation of America (AAFA).
• On January 11, 2022, The US Food & Drug Administration has given its final approval to Marksans Pharma Limited’s Abbreviated New Drug Application (ANDA) for OTC Cetirizine Hydrochloride Tablets, 5 mg, and 10 mg.

Similarly, recent developments related to companies within the seasonal allergy market space have been tracked by the team at Future Market Insights. These are available in the full report.

Key Companies Profiled

• Merck KGaA
• Johnson & Johnson
• Allergopharma
• Sanofi SA
• McNeil Consumer Healthcare,
• Genentech Inc.
• GlaxoSmithKline PLC
• Leti Pharma,
• Alerpharma S.A
• Allergan, Inc.
• Meda Pharmaceuticals, Inc
• Novartis International AG
• Bausch Health Companies Inc.
• Allergopharma
• ALK Abello
• Stallergenes Greer
• Allergy Therapeutics
• Aimmune Therapeutics
• Biomay AG
• HAL Allergy Group
• Bayer
• AstraZeneca

A Full Report Overview

Key Market Segments Covered in the Seasonal Allergy Industry Research

By Form:

• Tablets/Capsules
• Liquid
• Creams & Lotions
• Drops
• Spray

By Prescription:

• OTC
• Prescription based

By Route of Administration:

• Oral
• Intranasal
• Sublingual
• Sub Cutaneous
• Intravenous

By Treatment:

• Antihistamines
• Decongestants
• Nasal Corticosteroids
• Allergen Immunotherapy
• Leukotriene Receptor Antagonists

By Distribution Channel:

• Hospital Pharmacies
• Supermarkets/Hypermarkets
• Online Pharmacies
• Retail Pharmacies
• Speciality Clinics
• Others

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• The Middle East and Africa (MEA)

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube